Prognostic factor and risk stratification in hepatocellular carcinoma: insights from Cox regression and Kaplan-Meier analysis in a male-dominated cohort.

L C Nguyen, D T M Luu, H T N Doan, N M Nguyen, H T T Nguyen, T T Pham, N B Pham, T P Le, T T Nguyen, H V Nguyen
{"title":"Prognostic factor and risk stratification in hepatocellular carcinoma: insights from Cox regression and Kaplan-Meier analysis in a male-dominated cohort.","authors":"L C Nguyen, D T M Luu, H T N Doan, N M Nguyen, H T T Nguyen, T T Pham, N B Pham, T P Le, T T Nguyen, H V Nguyen","doi":"10.26355/eurrev_202412_37004","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality worldwide. This study aims to comprehensively evaluate the prognostic factors influencing survival in patients diagnosed with HCC.</p><p><strong>Patients and methods: </strong>This is a cross-sectional study aimed at identifying prognostic factors in HCC using Cox regression and Kaplan-Meier analysis. A cohort of 364 predominantly male HCC patients with a mean age of 61.6 ± 10.9 years was analyzed.</p><p><strong>Results: </strong>Significant risk factors for mortality included HCV infection, alcoholism, elevated alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA) II levels, and a Child-Pugh score of 8. HCV-positive patients had a hazard ratio (HR) of 2.25. Average survival time was 32.99 ± 31.64 months, with 1, 2, and 3-year survival rates of 73.6%, 44.5%, and 31.3%, respectively. Patients with PIVKA-II levels ≤ 125 mAU/mL had a significantly higher 50% chance of surviving 42 months. Patients with the Barcelona clinic liver cancer (BCLC) stage B1 displayed a higher survival rate, except at the 24-month time point, with BCLC A and B1 groups showing survival rates exceeding 80% in the first year.</p><p><strong>Conclusions: </strong>The findings provide valuable insights into the prognostic implications and risk stratification in HCC, facilitating personalized treatment decisions and potentially improving patient outcomes.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"28 24","pages":"4701-4711"},"PeriodicalIF":3.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European review for medical and pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26355/eurrev_202412_37004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality worldwide. This study aims to comprehensively evaluate the prognostic factors influencing survival in patients diagnosed with HCC.

Patients and methods: This is a cross-sectional study aimed at identifying prognostic factors in HCC using Cox regression and Kaplan-Meier analysis. A cohort of 364 predominantly male HCC patients with a mean age of 61.6 ± 10.9 years was analyzed.

Results: Significant risk factors for mortality included HCV infection, alcoholism, elevated alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA) II levels, and a Child-Pugh score of 8. HCV-positive patients had a hazard ratio (HR) of 2.25. Average survival time was 32.99 ± 31.64 months, with 1, 2, and 3-year survival rates of 73.6%, 44.5%, and 31.3%, respectively. Patients with PIVKA-II levels ≤ 125 mAU/mL had a significantly higher 50% chance of surviving 42 months. Patients with the Barcelona clinic liver cancer (BCLC) stage B1 displayed a higher survival rate, except at the 24-month time point, with BCLC A and B1 groups showing survival rates exceeding 80% in the first year.

Conclusions: The findings provide valuable insights into the prognostic implications and risk stratification in HCC, facilitating personalized treatment decisions and potentially improving patient outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.30
自引率
6.10%
发文量
906
审稿时长
2-4 weeks
期刊介绍: European Review for Medical and Pharmacological Sciences, a fortnightly journal, acts as an information exchange tool on several aspects of medical and pharmacological sciences. It publishes reviews, original articles, and results from original research. The purposes of the Journal are to encourage interdisciplinary discussions and to contribute to the advancement of medicine. European Review for Medical and Pharmacological Sciences includes: -Editorials- Reviews- Original articles- Trials- Brief communications- Case reports (only if of particular interest and accompanied by a short review)
期刊最新文献
Long-term blood pressure control assessment using time spent in therapeutic range among Saudi patients. Predictive factors for lack of neurological improvement in acute stroke patients without large vessel occlusion treated with low-dose thrombolysis and screened with 3T MRI. Retraction Note: Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer. Retraction Note: MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9. The role of the urinary microbiome on male benign prostatic hyperplasia (BPH) and its management using probiotic supplementation: a narrative review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1